As the results of the model simulations show, a reduction in the progression of the disease given by the estimated effect of the treatments: (1) SGLT2 inhibitors for those with diabetes mellitus in CKD stages 3a and 3b, and (2) pre-dialysis for those in CKD stages 4 and 5, would have a significant impact on the number of individuals advancing to later stages of the disease and therefore potential savings of around 214.6M GBP on direct costs for the Chilean healthcare system. The gene discussed is SLC5A2; the disease is diabetes mellitus.